Floatz logo

Cyclophosphamide

Hematopoietic/Lymphoid Cancer

National Cancer Institute (NCI)Small moleculePhase 3Active
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
95/ 100

Competitive context

136 Active assets in the Hematopoietic/Lymphoid Cancer cohort.

Asset / SponsorPhaseRating
Inno-206
OHSU Knight Cancer Institute
Phase 4BBB
DEXAMETHASONE
City of Hope Medical Center
Phase 3BB
Teclistamab
Janssen Pharmaceutical K.K.
Phase 2BB
Bortezomib
OHSU Knight Cancer Institute
Phase 4BB
ALLOGENEIC, EX VIVO EXPANDED, UMBILICAL CORD BLOOD-DERIVED HEMATOPOIETIC CD133+ PROGENITOR CELLS- CULTURED FRACTION (CF)
Gamida Cell ltd
Phase 3BB

View all 50 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →